Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could talk therapy boost brain function in schizophrenia?

NCT ID NCT07671040

Symptom relief Sponsor: Hasanuddin University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times

Summary

This pilot study tested whether adding structured supportive psychotherapy to the antipsychotic risperidone could improve cognitive function and reduce inflammation in 44 hospitalized adults with schizophrenia. Participants received either risperidone plus 12 weekly talk therapy sessions or risperidone plus unstructured conversation. The study measured changes in thinking skills and a blood marker of inflammation after 12 weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
structured supportive psychotherapy
What this could lead to
If this approach works, it could point toward a way to improve thinking skills and reduce inflammation in people with schizophrenia, alongside standard medication.
What could go wrong
This is a small pilot study with only 44 participants, so results may not apply to everyone. The trial was registered after completion, which can introduce bias.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

44 people

The number who actually took part.

Started

Mar 2025

Finished

Jun 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 45 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male and female inpatients diagnosed with schizophrenia according to DSM-5-TR criteria * Aged 20 to 45 years * In a post-acute stabilized residual phase * Total PANSS score between 60 and 70 * Receiving risperidone at a fixed dose of 4 mg per day * Willing and able to attend individual psychotherapy sessions throughout the 12-week trial period Exclusion Criteria: * Febrile conditions at time of screening * Organic comorbid diseases * Active infectious diseases * Obesity (body mass index ≥ 30 kg/m²) * Comorbid personality disorders * Concurrent use of anti-inflammatory medications or antioxidant supplements * Substance use disorder within the preceding 6 months

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cognitive and executive dysfunction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Neuroinflammatory Diseases neuronitis schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cognitive and executive dysfunction Neuroinflammation Schizophrenia

Contacts and locations

Locations

  • Department of Psychiatry, Faculty of Medicine, Hasanuddin University

    Makassar, South Sulawesi, 90245, Indonesia

More trials for these conditions

Other studies related to the condition(s) this trial covers.